

Unique Approach

Antibacterial

Antifungal

**Attacking AMR
Globally**

- Polymicrobial (fungal)
- Biofilm

Resistance
Breaker

Antibiofilm

First-in-Class Candidates

Antibacterial

Novarifyn® NP432

- Preclinical bactericidal peptide
- MDR bacterial infections, sepsis

Antifungal

Novamycin® NP339

- Clinical stage fungicidal peptide
- Aspergillosis

- Novel, intelligently designed biological therapies
- Agnostic WRT resistance status
 - MOA mitigates/negates development of future resistance

Resistance Breaker

Nylexa™ NM002/Lynovex® NM001


- Late clinical stage (CF); NM001
- Antibiotic chemopotential & AMR reversal; NM002

Antibiofilm

Lynovex® NM001

- Late stage clinical (CF)
- Bacterial & fungal biofilms

Parallel Development & Implementation



Novexatin®
NOVEL ANTIFUNGAL PEPTIDE BRUSH-ON TREATMENT FOR ONICHOMYCOSIS

Lynovex®
NOVEL MULTIACTIVE CANDIDATE THERAPY FOR CYSTIC FIBROSIS

Novamycin®
NOVEL ANTIFUNGAL PEPTIDE FOR TREATMENT OF FUNGAL INFECTIONS

Novarifyn®
ANTIBACTERIAL PEPTIDES FOR TREATMENT OF ANTIBIOTIC-RESISTANT INFECTIONS

Tackling AMR with an approach recognising the complexity/global nature of the problem & with novel drug candidates that circumvent existing & prevent/mitigate future AMR